Contact information
Colleges
Michael Desborough
BMedSci(Hons), MBChB, MRCP, FRCPath, DPhil
Consultant Haematologist & Honorary Senior Lecturer
The main focus of my research is assessing whether desmopressin could be used for treatment of thrombocytopenia or platelet dysfunction.
Platelets are a key part of clot formation. Patients with too few platelets, or platelets which are dysfunctional, are vulnerable to bleeding. One way to treat these patients is by transfusing platelets from a blood donor but this approach is often not effective. I am aiming to determine if desmopressin (a drug which increases platelet adhesion by stimulating release of Von Willebrand Factor) could be an effective adjuvant, or alternative treatment.
I am using a combination of methods to assess the value of desmopressin in this setting including meta-analysis of randomised controlled trials; laboratory assessment of thrombus formation under flow; and observational trials. I am leading two randomised placebo-controlled feasibility trials: desmopressin for prevention of bleeding in thrombocytopenia (DRIVE) and desmopressin for treatment of stroke due to haemorrhage (DASH).
Key publications
-
Desmopressin use for minimising perioperative blood transfusion.
Journal article
Desborough MJ. et al, (2017), Cochrane Database Syst Rev, 7
-
Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials.
Journal article
Desborough MJR. et al, (2017), J Thromb Haemost, 15, 263 - 272
-
Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials.
Journal article
Odutayo A. et al, (2017), Lancet Gastroenterol Hepatol, 2, 354 - 360
-
Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders.
Journal article
Thomas W. et al, (2021), J Thromb Haemost
-
Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom.
Journal article
Desborough MJR. et al, (2020), Thromb Res, 193, 1 - 4
Recent publications
-
Platelet transfusion and anticoagulation in haematological cancer-associated thrombosis and thrombocytopenia: the CAVEaT multi-centre prospective cohort.
Journal article
Booth S. et al, (2022), J Thromb Haemost
-
Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine: Comment from Doyle et al.
Journal article
Doyle AJ. et al, (2022), J Thromb Haemost, 20, 781 - 783
-
Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England.
Journal article
Higgins H. et al, (2022), Res Pract Thromb Haemost, 6
-
A single 1 g/kg dose of intravenous immunoglobulin is a safe and effective treatment for immune thrombocytopenia; results of the first HaemSTAR 'Flash-Mob' retrospective study incorporating 961 patients.
Journal article
HaemSTAR Collaborators None., (2021), Br J Haematol
-
Acquired Bernard-Soulier syndrome and hypodysfibrinogenaemia because of multiple myeloma.
Journal article
Sehgal T. et al, (2021), Blood Coagul Fibrinolysis
ORCID
0000-0002-1951-5616